Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NIZ985 + tislelizumab
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous (NIZ985), Intravenous (tislelizumab)
01
Overview
**NIZ985 + tislelizumab** is an investigational combination of two immunotherapy agents for cancer treatment. **NIZ985** is a recombinant human interleukin-15 heterodimer (IL-15 complexed with IL-15 receptor α), designed to stimulate the proliferation and activation of CD8+ T cells and natural killer cells to enhance antitumor immune responses. **Tislelizumab** is a monoclonal antibody targeting programmed cell death protein 1 (PD-1), blocking immune checkpoint signaling to facilitate immune-mediated tumor cell killing. This combination aims to potentiate immune system activity against malignancies, especially in tumors with resistance to prior checkpoint inhibitor therapy. The combination is primarily studied in advanced solid tumors and lymphoma, particularly in patients relapsed after immune checkpoint inhibitors.[5]
- Other names
- hetIL-15 + tislelizumabIL-15/sIL-15Rα + tislelizumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)
Beyond the preview
Go deeper on NIZ985 + tislelizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NIZ985 + tislelizumab.